Glide(US) | $15,000,000 | (May 9, 2025)
Kouper | $10,000,000 | (May 9, 2025)
PATH EX, Inc. | $5,000,000 | (May 9, 2025)
HAYA Therapeutics
Switzerland
- Lausanne
- 09/05/2025
- Series A
- $65,000,000
HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.
- Industry Biotechnology Research
- Website https://www.hayatx.com/
- LinkedIn https://www.linkedin.com/company/haya-therapeutics/
Related People
Samir OunzainCo Founder
Switzerland -
Lausanne, Vaud
I am the Co-Founder and CEO of HAYA Therapeutics, where we are on a mission to develop precise RNA-guided therapeutics to address serious health conditions, notably cardiovascular disease, fibrosis and cancer, by leveraging the power of the regulatory genome. Our proprietary cell-state modifying platform allows us to unearth new insights into the biology of long non-coding RNAs (lncRNAs), revealing the 'regulatory genomes' information processing features and 'source code’. Our lead candidate, HTX-001, targets Wisper, a cardiac-specific lncRNA implicated in heart failure, exemplifying our commitment to innovating patient care. We are also advancing a series of lncRNA-targeting candidates focused on specific cell-state treatment of diseases in various tissues, fortified by our strategic location in Biopôle, Lausanne, Switzerland, cutting-edge lab facilities at JLABS @ San Diego, and a team of experts in programmable and precision RNA-targeted therapeutics. With robust investor backing, we are passionate in our core mission to transcend existing treatments and transform patient care using programmable regulatory genome RNA medicines, combining innovative science, a dynamic pipeline, and a world-class team to bring the promise of the regulatory genome to life.
VESTIGAS | $9,003,240 | (May 9, 2025)
Una Software | $4,400,000 | (May 9, 2025)
Zebu Intelligent Systems Pvt Ltd | $1,000,000 | (May 9, 2025)
Jozu | $4,000,000 | (May 9, 2025)
Blank Beauty | Undisclosed Amount | (May 9, 2025)
Pulse Charter Connect | $2,000,000 | (May 9, 2025)
CodeAnt AI (YC W24) | $2,000,000 | (May 8, 2025)
Operand | $3,100,000 | (May 8, 2025)